Search

Displaying results 8271 - 8280 of 10000 in total
  1. Drug

    Surotomycin

    go.drugbank.com/drugs/DB12076
    Investigational

    It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. … Surotomycin has a fourfold greater in vitro potency than vancomycin against C.

  2. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria. … [A254232] UCB7362 is estimated to achieve a significant reduction in asexual blood-stage parasites.

  3. Drug

    Epofolate

    go.drugbank.com/drugs/DB12266
    Investigational

    Epofolate (BMS-753493) is a folate conjugate of the epothilone analog BMS-748285 that was designed to selectively target folate receptor expressing cancer cells. … tolerable and toxicities known to be associated with epothilone class of anticancer agents were common, although peripheral neuropathy and neutropenia appear to have been less frequent and less severe as

  4. Drug

    Robenidine

    go.drugbank.com/drugs/DB11542
    ExperimentalVet approved

    Robenidine is identified as a coccidiostat drug, which slows both the growth and reproductive cycles of coccidian parasites. … Robenidine is used to control coccidiosis, a lethal infection in poultry which has shown a significant economic burden.

  5. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    IMM-101 is a heat-inactivated immune-activating mycobacterial product. … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over

  6. Drug

    RG-7795

    go.drugbank.com/drugs/DB06329
    Investigational

  7. Drug

    TRC093

    go.drugbank.com/drugs/DB06356
    Investigational

    TRC093 is a recombinant humanized IgG1k monoclonal antibody.

  8. Drug

    LJP 1082

    go.drugbank.com/drugs/DB05446
    Experimental

    The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I. … LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    IMM-101

    go.drugbank.com/drugs/DB15850
    Investigational

    IMM-101 is a heat-inactivated immune-activating mycobacterial product. … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over

  10. Drug

    AVR118

    go.drugbank.com/drugs/DB04979
    Investigational

    AVR118 represents a new type of biopolymer chemistry that also possesses novel immunomodulator activity. … This non-toxic peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human